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One of the best-characterized oncogenic mechanisms
in breast cancer is the aberrant activation of
phosphatidylinositol-3-kinase, protein kinase B, and
mammalian target of rapamycin signaling. In both
endocrine-resistant disease and breast cancer stem cells,
this is commonly caused by specific genetic lesions or
amplification of key pathway components or both.
These observations have generated two interesting
hypotheses. Firstly, do these genetic anomalies provide
clinically significant biomarkers predictive of endocrine
resistance? Secondly, do tamoxifen-resistant breast
cancer cells emerge from a stem-like cell population?
New studies, published in Breast Cancer Research, raise the
possibility that these hypotheses are intrinsically linked.determining region Y-box, E2F transcription factor, andIn experimental models of estrogen receptor (ER)-positive
breast cancer, the hyperactivation of phosphatidylinositol-3-
kinase (PI3K), protein kinase B (AKT), and mammalian tar-
get of rapamycin (mTOR) can impede the inhibitory effect
of endocrine therapy. This hyperactivation can be caused
by augmented growth factor signaling, inactivation of
PI3K inhibitors such as phosphatase and tensin homologue,
and mutation and/or amplification of PI3K subunits
and activators. Although these aberrations are frequently
observed in human breast cancer, their clinical significance
in endocrine-resistant disease remains controversial. Recent
studies by Beelen and colleagues [1,2] and Lin and
colleagues [3] in Breast Cancer Research raise the possibility
that heterogeneity between different breast cancer cell
populations may contribute to divergent findings.* Correspondence: liz.musgrove@glasgow.ac.uk
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article, unless otherwise stated.Breast cancer stem cells (BCSCs) commonly harbor gain-
of-function mutations in key components of the PI3K/AKT/
mTOR signaling pathway [4,5]. For example, mutations in
PIK3CA, a gene encoding a catalytic subunit of PI3K, were
recently reported to be present in 8 out of 11 BCSC popula-
tions extracted from breast cancer specimens but absent in
normal mammary stem cells [4]. It is thought that such
attributes facilitate BCSC characteristics such as drug
resistance and tumor progression [5]. A growing body of
evidence suggests that endocrine-resistant breast cancer
cells may be derived from a stem-like cell population [3,6].
By interrogating the genetic and epigenetic profiles of
multiple tamoxifen-resistant cell lines, Lin and colleagues
[3] determined that both intrinsic and acquired resistance
were strongly associated with the deregulation of genes
related to pluripotency and differentiation, including sex-
retinoblastoma gene product family pocket proteins. This
suggests that resistant cells could emerge from discrete
populations of stem-like breast cancer cells. Because as few
as 100 BCSCs were able to form tumors in mice, whereas
tens of thousands of cells with alternative phenotypes failed
to form tumors [7], it is apparent that endocrine-resistant
BCSCs may represent a very small needle in a very large
haystack. It is therefore questionable whether molecular bio-
markers associated with this cell phenotype could be readily
detectable in primary disease for diagnostic purposes.
Much controversy surrounds the clinical significance of
PI3K/AKT/mTOR-associated biomarkers in breast cancer.
Some reports, including that of Beelen and colleagues [2],
suggest that PIK3CA mutation is associated with a longer
disease-free survival, lower tumor grade, and increased ER
expression [2,8,9], whereas others report an association
with poor survival rates [10] (recently reviewed in [11]). Im-
portantly, unlike other investigators, Beelen and colleagues
[2] were able to examine whether these mutations were
specifically associated with response to tamoxifen but didCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tamoxifen treatment and PI3KA mutation. It would be
interesting, based on the results of Lin and colleagues [3],
to determine whether the same was true if PI3KA mutation
rates were measured in BCSCs derived from the clinical
trial cohorts used by Beelen and colleagues, although this is
unlikely to be practicable.
Why would a PIK3CA mutation be predictive in some
breast cancer cell types but not others? Stem cells have a
greater propensity to accumulate genetic and epigenetic
modifications in order to acquire a survival advantage when
under selection pressure [12]. This phenomenon is further
evidenced by the demonstration that emergent ‘stem-like’
resistant populations featured methylomic modifications to
gene promoter regions associated with reduced expression
of genes that conferred survival [3]. With the emergence of
epigenetic biomarkers across multiple aspects of breast
cancer research, this highlights a potential use for DNA
methylation biomarkers as predictors of tamoxifen response
with prospective application in neo-adjuvant studies, as
discussed previously [13].
Biomarkers downstream of PI3K/AKT/mTOR signaling
may reflect pathway activation more accurately than acti-
vating mutations, since the effects of active signaling will be
amplified across the entire tumor cell population through
paracrine growth factor receptor pathways. In agreement
with this idea, Beelen and colleagues [1] demonstrated that
p-p70S6K, a phosphorylation target of mTOR, was predict-
ive of tamoxifen resistance in post-menopausal patients
with breast cancer but was associated with favorable prog-
nosis in patients from the same clinical trial who did not
receive tamoxifen. One could perhaps hypothesize that
there exists a mechanism by which residual ER signaling
limits the expansion of a BCSC population, similar to that
previously shown to regulate neural stem cells [14]. In
patients who received tamoxifen, inhibiting such regulation,
or indeed the acquired genetic and epigenetic changes that
are accumulated by residual breast cancer cells, could then
positively select for a more aggressive cell phenotype,
as previously suggested in experimental models [3,13].
Irrespective of the mechanistic basis for the predictive
power of p-p70S6K, as suggested by Beelen and colleagues,
p-p70S6K may provide a useful companion biomarker for
the mTOR inhibitor, everolimus, which has recently been
approved in Europe and the US in combination with endo-
crine therapy for the treatment of post-menopausal women
with endocrine-resistant disease [15].
Although our understanding of the origins of endocrine-
resistant breast cancer is constantly evolving, it is obvious
that the mechanisms that determine resistance are diverse,
complex, and dynamic. Endocrine-resistant disease still
represents one of the most challenging obstacles in breast
cancer treatment. The appropriate use of PI3K/AKT/
mTOR signaling pathway inhibitors remains to be refinedin endocrine resistance; however, clinical trials suggest that
their clinical impact will be considerable. To maximize
their therapeutic potential, it is critical that companion
biomarkers of response be further characterized.
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